## **Patient Journey Lynch Syndrome**



Network

www.genturis.eu

07-05-2019 Version 5.0 textual update 2023

## **Patient Journey Lynch Syndrome**

Disease	1 <sup>st</sup> symptoms	Referral to doctors and specialists	Cancer diagnosis	Treatment	Genetic testing	Follow-up care	
	Variety of cancer related symptoms Associated cancers: Colorectal (20-80%) Endometrial (15-60%) Ovary (1-38%) Stomach (1-13%) Small intestine Urinary tract etc.	Patient often has to see numerous doctors and specialists. Patient is subjected to numerous clinical tests.	Treatment / therapy plan is outlined. Patient has to decide on / agree to therapy options. Possibility to get a second opinion.	If Lynch Syndrome is diagnosed patient can decide on combined prophylactic surgery, dependent on gene involved: - Colon - Ovaries - Endometrium	<ol> <li>Counselling interview (1h)</li> <li>Patient receives result (approx. 2 month later)</li> <li>Patient is prompted to inform relatives about:         <ul> <li>genetic tumour risk</li> <li>genetic testing</li> <li>preventive examinations</li> </ul> </li> <li>In 30%-40% genetic mutation is not (yet) detected.</li> </ol>	After regular cancer treatment, Lynch syndrome patient should go into surveillance: Regular intervals for 5 years: -Physical examinations - Clinical tests Surveillance: Colonoscopy: 1-2 y Helicobacter pylori infection Skin examination	
Clinic	No history	Known history	If there is cancer diagnosis without Lynch Syndrome diagnosis patient is treated according to general guidelines. Patient can only decide on prophylactic surgery when Lynch Syndrome diagnosis is confirmed.		Relatives cannot or do not want to be tested, but are also recommended to follow screening programs for cancer prevention: - Colonoscopy: 1-2 y - Helicobacter pylori infection - Skin examination	Risk reducing surgery dependent	
	Initially cancer is not assumed because of atypical clinical appearance: - Young age - Lack of classical risk factors (e.g. overweight, smoking)	Screening: Colonoscopy: 1-2 y Helicobacter pylori infection Skin examination Risk reducing surgery: Uterus Ovary Colon				on gene involved: Uterus Ovary Colon	
Challenge			Treatment often starts before		Recommendation		
Challenge	E Early detection		Lynch Syndrome diagnosis		targeted treatment	Long journey after cancer until Lynch Syndrome diagnosis	
					unclear		
	Physicians should be aware of genetic tumour risk syndromes and consider cancer at early age, especially in case of positive family history. Quick and correct referral to specialists. Early detection and treatment are crucial for outcome!		Not every Lynch Syndrome patients is aware of Lynch Syndrome before cancer treatment. Referral to expert to receive a valuable second opinion. Awareness of both physical and psychic side effects.		Recommendations for treat- ment of Lynch Syndrome tumours Considering its characteristics: - High immunogenicity - Lower metastasis rate - High risk of developing another cancer after treatment	Every patient should receive their diagnosis as soon as possible, to be able to have benefit from screening programs and/or preventive surgery. Currently not all patients are diagnosed and they and their family members do not receive the care they need.	
Goal	Awareness and education for GPs and clinicians	Psychological support		e specific treatment empowerment	Support on how to inform relatives	Personalized follow-up	
	GPs and clinicians should identify red flegs associated with tumour risk syndromes. Education and raising awareness of genetic tumor risks among GPs and physicians.	Physician directly suggests psychological support in diagnosis phase to deal with consequences for patients and relatives.		atment. y for MMR proteins in colorectal r helps to recognise Lynch Syndrome tumour.	Psychological support on coping with lifetime tumor risk for patient as well as for family. Clear recommandations on when, and how to inform relatives.	Organize follow-up together with the patient, consider: Physical care Psychological care Family planning Social consequence e.g. mortgage	
European Reference Network	Genetic Tumour Risk Synd (ERN GENTURIS)	Genetic Tumour Risk Syndromes (ERN GENTURIS)Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the granting authority (European Health and Digital Executive Agency (HaDEA)). Neither the European Union nor the granting authority can be held responsible for themImage: Comparison of the author (s) only and do not necessarily reflect those of the European Union or the granting authority (European Health and Digital Executive Agency (HaDEA)). Neither the European Union nor the granting authority can be held responsible for themImage: Comparison of the author (s) only and do not necessarily reflect those of the European Union or the granting authority (European Health and Digital Executive Agency (HaDEA)). Neither the European Union nor the granting authority can be held responsible for themImage: Comparison of the European Union or the granting authority (European Health and Digital Executive Agency (HaDEA)). Neither the European Union nor the granting authority can be held responsible for themImage: Comparison of the European Union or the granting authority can be held responsible for them					

